Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Seeking Alpha7/31/2026Neutral
FLGT
Fulgent Genetics IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$510.68M
P/E Ratio
—
EPS
$-2.83
Beta
0.91
52W High
$31.04
52W Low
$13.46
50-Day MA
$19.38
200-Day MA
$21.13
Dividend Yield
—
Profit Margin
-26.10%
Forward P/E
7.70
PEG Ratio
1.32
About Fulgent Genetics Inc
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Fundamentals
| Revenue (TTM) | $323.93M |
| Gross Profit (TTM) | $115.26M |
| EBITDA | $-89.46M |
| Operating Margin | -39.40% |
| Return on Equity | -8.11% |
| Return on Assets | -6.30% |
| Revenue/Share (TTM) | $10.74 |
| Book Value | $36.40 |
| Price-to-Book | 0.51 |
| Price-to-Sales (TTM) | 1.58 |
| EV/Revenue | 0.814 |
| EV/EBITDA | 2.34 |
| Quarterly Earnings Growth (YoY) | -98.60% |
| Quarterly Revenue Growth (YoY) | 4.40% |
| Shares Outstanding | $27.52M |
| Float | $16.69M |
| % Insiders | 37.81% |
| % Institutions | 59.12% |
Historical Volatility
HV 10-Day
32.09%
HV 20-Day
81.25%
HV 30-Day
67.71%
HV 60-Day
56.77%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($19.00 target)
1
HoldLatest News
Fulgent Genetics: Strong Moves By Management Keep Me Bullish
Fulgent Genetics remains a long-term play, supported by a strong balance sheet and disciplined capital allocation. Recent opportunistic share repurchases at $15.42/share and insider buying highlight management's conviction in FLGT's intrinsic value. FLGT trades below tangible book value, with net assets per share estimated at $24.09–$29, offering a margin of safety.
Seeking Alpha7/13/2026Positive
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer que.
Business Wire7/9/2026Neutral
Fulgent Presents Updated FID-007 Data at ASCO 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled “FID.
Business Wire6/1/2026Neutral
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.
GlobeNewsWire5/22/2026Neutral
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.
GlobeNewsWire5/8/2026Neutral
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.
Business Wire5/4/2026Neutral
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Seeking Alpha5/1/2026Neutral
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.04 per share a year ago.
Zacks Investment Research5/1/2026Neutral
Fulgent Reports First Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2026. First Quarter 2026 Results: Revenue of $71.1 million GAAP loss of $24.8 million, or $(0.80) per share Non-GAAP loss of $11.0 million, or $(0.36) per share Adjusted EBITDA loss of $15.2 million Non-.
Business Wire5/1/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FLGT and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026